Published online before print February 7, 2005, doi: 10.1161/01.HYP.0000154365.30593.d3
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Hypertension. 2005;45:773.)
© 2005 American Heart Association, Inc.
Original Articles |
Aldosterone Activates Vascular p38MAP Kinase and NADPH Oxidase Via c-Src
From CIHR Multidisciplinary Research Group on Hypertension (G.E.C., R.M.T., Y.H., S.M., E.L.S.), Clinical Research Institute of Montreal, University of Montreal, Canada; and the Department of Pharmacology (R.C.T., A.Y.), Institute of Biomedical Sciences, University of Sao Paulo, Brazil.
Correspondence to Glaucia E. Callera, Clinical Research Institute of Montreal, 110 Pine Ave, West Montreal, Quebec H2W 1H7. E-mail callereg{at}ircm.qc.ca
 |
Abstract |
|---|
 Top Abstract IntroductionMethodsResultsDiscussionReferences |
|---|
Increasing evidence indicates that aldosterone elicits vascular effects through nongenomic signaling pathways. We tested the hypothesis that aldosterone induces activation of vascular mitogen-activated protein (MAP) kinases and NADPH oxidase via c-Src–dependent mechanisms in vascular smooth muscle cells (VSMCs). Aldosterone effects on activation of c-Src, p38MAP kinase, and NADPH oxidase, and incorporation of [3H]proline, an index of collagen synthesis, were assessed in cultured rat VSMCs. Studies were performed in the absence and presence of eplerenone, a selective mineralocorticoid receptor blocker, PP2, a selective Src inhibitor, and SB212190, a selective p38MAPK inhibitor. Phosphorylation of c-Src was dose-dependently increased by aldosterone, with maximal responses obtained at 10–7 mol/L. Aldosterone increased p38MAP kinase phosphorylation, NAD(P)H oxidase activation, and [3H]proline incorporation. These responses were abrogated by eplerenone and almost abolished by PP2. Aldosterone-stimulated incorporation of [3H]proline was significantly reduced by SB212190, indicating that p38MAP kinase plays a role in profibrotic actions of aldosterone. To unambiguously demonstrate the importance of aldosterone in c-Src signaling, VSMCs from c-Src+/+ and c-Src+/– mice were also studied. Aldosterone increased phosphorylation of c-Src, p38MAP kinase, and cortactin, a Src-specific substrate, in c-Src+/+ VSMCs, but not in c-Src-deficient cells. Taken together, our findings demonstrate that nongenomic signaling by aldosterone occurs through c-Src–dependent pathways. These processes may play an important role in profibrotic actions of aldosterone.
Key Words: aldosterone • mineralocorticoids • oxidative stress • vasculature • signal transduction • collagen
|
Introduction |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Aldosterone, a mineralocorticoid hormone that classically acts via intracellular mineralocorticoid receptors (MRs), is a key regulator of blood pressure and electrolytic balance.1,2 Aldosterone also plays an important pathophysiological role in hypertension and cardiovascular diseases by promoting changes in vascular reactivity and endothelial function, cardiovascular fibrosis, tissue remodeling, inflammation, and oxidative stress.3–7 Some of these events occur through angiotensin II (Ang II)–dependent pathways.8–10
Binding of aldosterone to intracellular MRs, which belong to the superfamily of ligand-regulated transcription factors, causes dissociation of the ligand-activated MR from a multiprotein complex containing molecular chaperones, translocation of the ligand–MR complex to the nucleus, and interactions with the regulatory region of target gene promoters. Aldosterone-induced genomic effects are characterized by a delay corresponding to a long series of subcellular events.1,2
Besides its well-known genomic actions, there is evidence of aldosterone-mediated short-term effects. Aldosterone induces rapid cellular responses by interfering with intracellular Ca2+ and cAMP levels, Na+/H+ exchanger activity, and phosphorylation of signaling molecules including protein kinase C, epidermal growth factor receptor, and mitogen-activated protein kinases (MAPKs), c-Jun NH2-terminal kinase (JNK) and extracellular signal-regulated kinases (ERKs) 1/2.11–18 Activation of these pathways are known to be critically involved in vascular smooth muscle cell (VSMC) processes associated with remodeling, inflammation, and altered tone in hypertension.19
Recent studies have demonstrated that aldosterone induces phosphorylation of c-Src in renal cortical and Chinese hamster ovary cells.20,21 The c-Src is abundantly expressed in VSMCs and rapidly activated by G-protein–coupled receptors. Furthermore, c-Src plays an important role in phospholipase C phosphorylation, inositol 1,4,5-trisphosphate formation, and Ca2+ mobilization. Src also induces activation of MAPKs (p38MAPK, JNK, and ERK1/2) associated with cell growth, apoptosis, and collagen deposition, as well as activation of other downstream proteins including focal adhesion kinase, Pyk2, and paxillin, involved in cell adhesion processes.19 In addition, c-Src is a critical proximal regulator of reduced nicotinamide adenine dinucleotide (phosphate) [NAD(P)H] oxidase-driven superoxide anion generation.22,23 Of clinical relevance, recent studies have highlighted the contribution of c-Src in molecular and cellular processes underlying vascular changes that occur in human and experimental hypertension.24,25
MRs do not have intrinsic kinase activity and molecular mechanisms underlying nongenomic actions of aldosterone in VSMCs are not fully understood. In the present study, we questioned whether c-Src plays a role in signaling pathways to mediate aldosterone-induced short-term vascular effects. Our findings demonstrate that aldosterone rapidly increases activation of p38MAP kinase and NAD(P)H oxidase through c-Src–dependent pathways. Profibrotic action of aldosterone, assessed by determining 3H-proline incorporation, marker of collagen synthesis, was also dependent on c-Src–regulated p38MAP kinase. These data provide novel insights into nongenomic signaling by aldosterone and highlight the importance of c-Src in these processes.
|
Methods |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Cell Culture
The study was approved by the Animal Ethics Committee of the Clinical Research Institute of Montreal and performed according to the recommendations of the Canadian Council for Animal Care. VSMCs from adult male Wistar-Kyoto rats (WKY), c-Src+/– mice, heterozygous for a disruption in the c-Src gene, and wild-type c-Src+/+ mice were studied. The c-Src+/– mice were generated from a c-Src+/– F1 cross26 and were genotyped by polymerase chain reaction. Rats (16 weeks old) and mice (8 to 10 weeks old) were euthanized by decapitation. VSMCs derived from mesenteric arteries were isolated and characterized as described in detail previously.27 Briefly, arteries were cleaned of adipose and connective tissue; VSMCs were dissociated by digestion of vascular arcades with enzymatic solution (collagenase, elastase, soybean trypsin inhibitor, and bovine serum albumin type I) during 30 to 60 minutes at 37°C; the tissue was filtered; and the cell suspension was centrifuged and resuspended in Dulbecco modified Eagle medium containing 10% fetal calf serum, 2 mmol/L glutamine, 20 mmol/L HEPES (pH 7.4), and antibiotics. At subconfluence, the culture medium was replaced with serum-free medium for 24 hours to render the cells quiescent. Low-passage cells (passages 1 to 7) were studied. The concentrations of pharmacological agents that we used were based on previous studies, which demonstrated that at these doses the signaling pathways were completely abolished.28–30
Western Blotting
VSMCs from WKY rats were stimulated with aldosterone (0.1 nmol/L to 1 µmol/L) for 60 minutes. The concentration of aldosterone that induced maximal c-Src phosphorylation (0.1 µmol/L) was used in further studies. VSMCs were stimulated with aldosterone (1 to 60 minutes), and in some experiments cells were pre-exposed for 30 minutes to 10 µmol/L eplerenone (selective aldosterone receptors antagonist) or 10 µmol/L PP2 (selective Src inhibitor). Proteins were extracted from VSMCs, separated by electrophoresis on a 10% polyacrylamide gel, and transferred onto a nitrocellulose membrane as previously described.25 Nonspecific binding sites were blocked with 5% skim milk in Tris-buffered saline solution with Tween for 1 hour at 24°C. Membranes were then incubated with phospho-specific antibodies (1:1000) overnight at 4°C. Antibodies were as follows: anti–c-Src (pY418) (Biosource), anti-p38MAPK (pY180/102) (Cell Signaling); and anti-cortactin (pY421) (Upstate). The respective nonphospho-antibodies were also used in the present study. After incubation with secondary antibodies, signals were revealed with chemiluminescence, visualized by autoradiography, and quantified densitometrically.
Determination of Proline Incorporation
[3H]proline incorporation was considered a marker of collagen deposition and was measured according to the protocol of Dubey et al.31 Quiescent cells were stimulated for 24 hours with aldosterone (0.01 nmol/L to 1 0.1 µmol/L). In some experiments, cells were pre-exposed to eplerenone, PP2, or SB212190 (a selective p38MAPK inhibitor) (10 µmol/L) and stimulated with aldosterone 0.1 µmol/L.
Measurement of NAD(P)H Oxidase Activity
VSMCs were stimulated with 0.1 µmol/L aldosterone (1 to 60 minutes). In some experiments, cells were pre-exposed for 30 minutes to eplerenone, and PP2 (10 µmol/L) and stimulated with aldosterone for 60 minutes, when activity of the oxidase was maximal. Cells were washed in ice-cold phosphate-buffered saline, scraped off in lysis buffer (20 mmol/L KH2PO4, 1 mmol/L EGTA, and protease inhibitors, pH 7.4), transferred to Eppendorf tubes, and sonicated for 3 seconds. The lucigenin-derived chemiluminescence assay was used to determine NAD(P)H oxidase activity in total protein cell homogenates. The reaction was started by the addition of NAD(P)H (0.1 mmol/L) to the suspension (250 µL final volume) containing sample (50 µL), lucigenin (5 µmol/L), and assay phosphate buffer (50 mmol/L KH2PO4, 1 mmol/L EGTA, 150 mmol/L sucrose, pH 7.4). Luminescence was measured every 1.8 seconds for 3 minutes in a luminometer (Lumistar Galaxy; BMG Labtechnologies). Buffer blank was subtracted from each reading. Activity was expressed as arbitrary units/mg protein.
Data Analysis
Aldosterone-stimulated effects were determined as the percent increase over control, with the control normalized to 100%. Results are presented as mean±SEM and compared by ANOVA or by the Student t test when appropriate. Values of P<0.05 were considered to be significant.
|
Results |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Aldosterone Effects on c-Src and p38MAPK Phosphorylation in VSMCs From WKY
Figure 1 demonstrates that aldosterone induces concentration-dependent phosphorylation of c-Src in VSMCs from WKY. Maximal c-Src phosphorylation was observed with 0.1 µmol/L of aldosterone, and this concentration was used in further studies. As shown in Figure 2, c-Src phosphorylation was time-dependently increased by aldosterone, with a small response occurring within 1 to 5 minutes, followed by a maximal response at 30 minutes. Aldosterone receptor antagonism with eplerenone, as well as inhibition of c-Src with PP2, reduced aldosterone-induced c-Src activation. Aldosterone induced a biphasic increase in p38MAPK activation with a peak response obtained within 1 minute, followed by a second response within 30 minutes (Figure 3). PP2 pretreatment inhibited aldosterone-induced p38MAPK activation. Total protein expression of c-Src and p38MAPK was unaltered by aldosterone stimulation.
|
|
|
Aldosterone Effects on Phosphorylation of cSrc and p38MAPK in VSMCs From c-Src–Deficient Mice
As shown in Figure 4A, aldosterone-induced maximal c-Src phosphorylation was observed at 1 minute and was sustained for up to 30 in VSMCs from wild-type c-Src+/+ mice. The c-Src phosphorylation was not significantly altered by aldosterone in VSMCs from c-Src+/– mice. Aldosterone also stimulated phosphorylation of cortactin in VSMCs from wild type c-Src+/+ mice (Figure 4B), but not in c-Src–deficient mice. Aldosterone significantly increased phosphorylation of p38MAPK in c-Src+/+ VSMCs, but not in c-Strc+/– cells (Figure 5).
|
|
Aldosterone Effects on NAD(P)H Oxidase Activity
In VSMCs cells from WKY, aldosterone induced a time-dependent increase in NAD(P)H-oxidase activity with maximal effect at 60 minutes, as assessed by low-dose lucigenin chemiluminescence (Figure 6A). Aldosterone also increased NADPH-oxidase activity in VSMCs from wild-type c-Src+/+ mice (234.6±4 arbitrary units/mg protein), whereas in VSMCs from c-Src+/– the response was significantly lower (100.5±1 arbitrary units/mg protein). Figure 6B shows that pretreatment with eplerenone or PP2 significantly reduced aldosterone-mediated activation of NAD(P)H oxidase in VSMCs cells from WKY. Neither PP2 nor eplerenone influenced the basal state of NAD(P)H oxidase activity. In the absence of NAD(P)H, lucigenin-derived chemiluminescence was almost undetectable (data not shown). A possible explanation for this finding is that basal superoxide anion in VSMCs from WKY rats is very low.
|
Aldosterone Effects on [3H]Proline Incorporation
Aldosterone induced a concentration-dependent increase in [3H]proline incorporation, a marker of collagen synthesis, in VSMCs from WKY rats (Figure 7A). Eplerenone did not change the basal levels of [3H]proline incorporation and inhibited aldosterone effects in VSMCs from WKY rats (Figure 7B). PP2 and SB212190 decreased basal levels of [3H]proline incorporation. In the presence of these inhibitors, aldosterone stimulation did not change [3H]proline incorporation (Figure 7B). [3H]proline incorporation increased in a dose-dependent manner in response to aldosterone in VSMCs from c-Src+/+ (aldosterone 0.1 µmol/L: 140.7±12% of basal), whereas in cells from c-Src+/– aldosterone did not induce [3H]proline incorporation. PP2 and eplerenone inhibited aldosterone-induced [3H]proline incorporation in c-Src+/+ VSMCs (data not shown).
|
|
Discussion |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Aldosterone can elicit rapid nongenomic effects, both in vivo and in vitro. Major findings of the present study demonstrate that aldosterone induces rapid activation of p38MAPK and NAD(P)H oxidase through c-Src–dependent pathways in VSMCs. These phenomena are associated with profibrotic processes, as evidenced by increased3[H]proline incorporation in response to aldosterone.
Multiple signaling pathways are activated by aldosterone, of which protein kinase C, epidermal growth factor receptor, ERK 1/2, and JNK cascades are best characterized.11–14 Src kinases are a family of nonreceptor tyrosine kinases, of which the prototype, c-Src, is the major isoform in the vasculature.19 By using a phospho-specific antibody that recognizes the activated site of c-Src, we demonstrated that aldosterone increases c-Src phosphorylation in rat mesenteric VSMCs. The ability of aldosterone to induce c-Src phosphorylation was lost in the presence of PP2, a selective c-Src inhibitor. To unambiguously demonstrate the importance of c-Src in aldosterone-mediated events, we also examined VSMCs from c-Src–deficient mice. Aldosterone increased phosphorylation of c-Src in c-Src+/+ VSMCs, with blunted effects in c-Src+/– cells. To further support a role of c-Src in aldosterone signaling and to evaluate the functional significance of c-Src activation, we assessed aldosterone actions on phosphorylation of cortactin. Cortactin, an actin-binding protein, is a Src-specific downstream target of c-Src tyrosine kinase signaling and plays an important role in regulating actin assembly and organization.32 Aldosterone stimulated cortactin phosphorylation in c-Src+/+ VSMCs, but not in Src+/– cells.
VSMCs express multiple MAPKs, including ERK1/2, a major growth-signaling kinase, JNK, and p38MAPK, involved in cell survival, apoptosis, differentiation, inflammation, and collagen deposition.19 Because MAPKs are downstream targets involved in c-Src signaling, we questioned whether aldosterone induces c-Src–dependent MAPK activation, specifically p38MAPK, in VSMCs. We observed a biphasic increase in p38MAP kinase activation by aldosterone in rat VSMCs, with an acute response within 1 to 3 minutes, followed by a sustained effect at 30 minutes. PP2 inhibited aldosterone-induced p38MAP kinase phosphorylation, indicating that c-Src is upstream of p38MAP kinase. Maximal activation of c-Src was temporally dissociated from the acute p38MAP kinase response, suggesting that even a modest activation of c-Src by aldosterone is sufficient to induce p38MAP kinase activation. Confirming the pharmacological data, aldosterone was not able to induce p38MAPK phosphorylation in cells from c-Src–deficient mice. Previous studies demonstrated that p38MAPK phosphorylation is important in collagen production.5–7 Here we show that aldosterone stimulates [3H]proline incorporation through a c-Src p38MAP kinase-regulated pathway in VSMCs, as evidenced by findings using PP2 and SB212190. The c-Src and p38MAPK activity are also important for basal protein synthesis, particularly collagen, because PP2 and SB212190 decreased basal [3H]proline incorporation.
Because aldosterone has also been linked to oxidative stress,33,34 it is of functional relevance to evaluate whether aldosterone short-term effects are associated with activation of redox-sensitive pathways. Our data demonstrate that aldosterone induces c-Src–dependent NAD(P)H oxidase activation. Because c-Src appears to be both upstream and downstream of NAD(P)H oxidase,19,22,23 activation of c-Src by aldosterone could result in amplification of NAD(P)H oxidase-mediated generation of reactive oxygen species and, consequently, oxidative stress-induced vascular damage. Moreover, redox-sensitive pathways are important in vascular remodeling through activation of MAPK events that underlie vascular functional, structural, and mechanical effects of aldosterone.19
The identity of the primary effector on aldosterone short-term effects—an unidentified membrane-bound receptor, the classical MR, or a related protein—is undergoing debate. Specific high-affinity binding sites for aldosterone have been characterized in membranes from different cells.35 Moreover, it was reported that aldosterone increased intracellular Ca2+ and cAMP levels in cultured skin cells from MR knockout mice, indicating that these rapid actions still occur in the absence of classical MRs.36 Conflicting reports have been demonstrated that nongenomic effects of aldosterone are not blocked by the classical MR antagonist, spironolactone. As examples, MR antagonists do not block aldosterone-induced changes in intracellular cAMP in VSMCs or ERK activation in cortical collecting duct cell.18,37 Conversely, others have demonstrated that MR antagonism inhibited signaling cascades activated by aldosterone.10,12,21 In agreement with these studies, we found that eplerenone, a selective MR antagonist, inhibited phosphorylation of c-Src and p38MAPK, as well as activation of NAD(P)H oxidase activity and [3H]proline incorporation induced by aldosterone. Taken together, these observations indicate that at least some of the rapid nongenomic effects of aldosterone may be mediated by activation of the classical MRs.
In conclusion, c-Src is an important signaling molecule in aldosterone-induced rapid effects in VSMCs. Aldosterone regulates MAP kinases and NAD(P)H-inducible generation of superoxide anion through c-Src–dependent mechanisms. Functional effectors of these processes may be associated with increased collagen production as evidenced by altered incorporation of [3H]-proline.
Perspectives
The present study demonstrates that c-Src plays an important role in aldosterone-mediated actions in VSMCs. We identify a novel nongenomic signaling pathway for aldosterone, involving c-Src–regulated activation of p38MAP kinase and NAD(P)H oxidase. Activation of this pathway may be important in the profibrotic actions of aldosterone. Although the exact mechanisms linking aldosterone to c-Src and the receptors through which aldosterone induces rapid nongenomic vascular actions remain unclear, findings from our studies highlight the functional importance of c-Src/p38MAP kinase/NAD(P)H oxidase and could help to identify molecular mechanisms contributing to aldosterone-mediated nongenomic effects in (patho)physiology. By elucidating such mechanisms, a better understanding to how drugs, such as eplerenone, may have therapeutic potential in hypertension.
|
Acknowledgments |
|---|
This study was supported by grants 44018 (to R.M.T.), 37917 (to E.L.S.), and a Group Grant to the Multidisciplinary Research Group on Hypertension, all from the Canadian Institutes for Health Research and an educational grant from Pharmacia/Pfizer. R.M.T. and G.C. received scholarships from the Fonds de la Recherché en Sante du Quebec and the Quebec Hypertension Society, respectively.
Received October 11, 2004; first decision November 4, 2004; accepted December 15, 2004.
|
References |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
1. Fejes-Toth G, Pearce D, Naray-Fejes-Toth A. Subcellular localization of mineralocorticoid receptors in living cells: effects of receptor agonists and antagonists. Proc Natl Acad Sci U S A. 1998; 95: 2973–2978.
2. Arriza JL, Weinberger C, Cerelli G, Glaser TM, Handelin BL, Housman DE, Evans RM. Cloning of human mineralocorticoid receptor complementary DNA: structural and functional kinship with the glucocorticoid receptor. Science. 1987; 237: 268–275.
3. Funder J. Mineralocorticoids and cardiac fibrosis: the decade in review. Clin Exp Pharmacol Physiol. 2001; 28: 1002–1006.[CrossRef][Medline] [Order article via Infotrieve]
4. Blasi ER, Rocha R, Rudolph AE, Blomme EA, Polly ML, McMahon EG. Aldosterone/salt induces renal inflammation and fibrosis in hypertensive rats. Kidney Int. 2003; 63: 1791–1800.[CrossRef][Medline] [Order article via Infotrieve]
5. Fiebeler A, Haller H. Participation of the mineralocorticoid receptor in cardiac and vascular remodeling. Nephron Physiol. 2003; 94: 47–50.[CrossRef]
6. Brown NJ. Eplerenone: Cardiovascular Protection. Circulation. 2003; 107: 2512–2518.
7. Bernhard MW, Schmidt BMW, Schmieder RE. Aldosterone-induced cardiac damage: focus on blood pressure independent effects. Am J Hypertens. 2003; 16: 80–86.[CrossRef][Medline] [Order article via Infotrieve]
8. Virdis A, Neves MF, Amiri F, Viel E, Touyz RM, Schiffrin EL. Spironolactone improves angiotensin-induced vascular changes and oxidative stress. Hypertension. 2002; 40: 504–510.
9. Michel F, Ambroisine ML, Duriez M, Delcayre C, Levy BI, Silvestre JS. Aldosterone enhances ischemia-induced neovascularization through angiotensin II-dependent pathway. Circulation. 2004; 109: 1933–1937.
10. Mazak I, Fiebeler A, Muller DN, Park JK, Shagdarsuren E, Lindschau C, Dechend R, Viedt C, Pilz B, Haller H, Luft FC. Aldosterone potentiates angiotensin II-induced signaling in vascular smooth muscle cells. Circulation. 2004; 109: 2792–2800.
11. Manegold JC, Falkenstein E, Wehling M, Christ M. Rapid aldosterone effects on tyrosine phosphorylation in vascular smooth muscle cells. Cell Mol Biol. 1999; 45: 805–813.[Medline] [Order article via Infotrieve]
12. Liu SL, Schmuck S, Chorazcyzewski JZ, Gros R, Feldman RD. Aldosterone regulates vascular reactivity: short-term effects mediated by phosphatidylinositol 3-kinase-dependent nitric oxide synthase activation. Circulation. 2003; 108: 2400–2406.
13. Krug AW, Grossmann C, Schuster C, Freudinger R, Mildenberger S, Govindan MV, Gekle M. Aldosterone stimulates epidermal growth factor receptor expression. J Biol Chem. 2003; 278: 43060–43066.
14. Christ M, Wehling M. Rapid actions of aldosterone: lymphocytes, vascular smooth muscle and endothelial cells. Steroids. 1999; 64: 35–41.[CrossRef][Medline] [Order article via Infotrieve]
15. Wehling M, Ulsenheimer A, Schneider M, Neylon C, Christ M. Rapid effects of aldosterone on free intracellular calcium in vascular smooth muscle and endothelial cells: subcellular localization of calcium elevations by single cell imaging. Biochem Biophys Res Commun. 1994; 204: 475–481.[CrossRef][Medline] [Order article via Infotrieve]
16. Gekle M, Golenhofen N, Oberleithner H, Silbernagl S. Rapid activation of Na+/H+ exchange by aldosterone in renal epithelial cells requires Ca2+ and stimulation of a plasma membrane proton conductance. Proc Natl Acad Sci U S A. 1996; 93: 10500–10504.
17. Wehling M, Neylon CB, Fullerton M, Bobik A, Funder JW. Nongenomic effects of aldosterone on intracellular Ca2+ in vascular smooth muscle cells. Circ Res. 1995; 76: 973–979.
18. Christ M, Gunther A, Heck M, Schmidt BM, Falkenstein E, Wehling M. Aldosterone, not estradiol, is the physiological agonist for rapid increases in cAMP in vascular smooth muscle cells. Circulation. 1999; 99: 1485–1491.
19. Touyz RM. Recent advances in intracellular signalling in hypertension. Curr Opin Nephrol Hypertens. 2003; 12: 165–174.[CrossRef][Medline] [Order article via Infotrieve]
20. Krug AW, Schuster C, Gassner B, Freudinger R, Mildenberger S, Troppmair J, Gekle M. Human epidermal growth factor receptor-1 expression renders chinese hamster ovary cells sensitive to alternative aldosterone signaling. J Biol Chem. 2002; 277: 45892–45897.
21. Braun S, Losel R, Wehling M, Boldyreff B. Aldosterone rapidly activates Src kinase in M-1 cells involving the mineralocorticoid receptor and HSP84. FEBS Lett. 2004; 570: 69–72.[CrossRef][Medline] [Order article via Infotrieve]
22. Touyz RM, Yao G, Schiffrin EL. c-Src induces phosphorylation and translocation of p47phox role in superoxide generation by angiotensin II in human vascular smooth muscle cells. Arterioscler Thromb Vasc Biol. 2003; 23: 981–987.
23. Seshiah PN, Weber DS, Rocic P, Valppu L, Taniyama Y, Griendling KK. Angiotensin II stimulation of NAD(P)H oxidase activity. Upstream mediators. Circ Res. 2002; 91: 406–413.
24. Touyz RM, He G, Wu XH, Park JB, Mabrouk ME, Schiffrin EL. Src is an important mediator of extracellular signal-regulated kinase 1/2–dependent growth signaling by angiotensin II in smooth muscle cells from resistance arteries of hypertensive patients. Hypertension. 2001; 38: 56–64.
25. Touyz RM, Wu XH, He G, Salomon S, Schiffrin EL. Increased angiotensin II-mediated Src signaling via epidermal growth factor receptor transactivation is associated with decreased C-terminal Src kinase activity in vascular smooth muscle cells from spontaneously hypertensive rats. Hypertension. 2002; 39: 479–485.
26. Soriano P, Montgomery C, Geske R, Bradley A. Targeted disruption of the c-Src proto-oncogene leads to osteoporosis in mice. Cell. 1991; 64: 693–702.[CrossRef][Medline] [Order article via Infotrieve]
27. Touyz RM, Tolloczko B, Schiffrin EL. Mesenteric vascular smooth muscle cells from SHR display increased Ca2+ responses to angiotensin II but not to endothelin–1. J Hypertens. 1994; 12: 663–673.[Medline] [Order article via Infotrieve]
28. Touyz RM, Wu XH, He G, Park JB, Chen X, Vacher J, Rajapurohitam V, Schiffrin EL. Role of c-Src in the regulation of vascular contraction and Ca2+ signaling by angiotensin II in human vascular smooth muscle cells. J Hypertens. 2001; 19: 441–449.[CrossRef][Medline] [Order article via Infotrieve]
29. Touyz RM, He G, El Mabrouk M, Schiffrin EL. p38 Map kinase regulates vascular smooth muscle cell collagen synthesis by angiotensin II in SHR but not in WKY. Hypertension. 2001; 37: 574–580.
30. Michea L, Delpiano AM, Hitschfeld C, Lobos L, Lavandero S, Marusic ET. Eplerenone blocks nongenomic effects of aldosterone on the Na+/H+ exchanger, intracellular Ca2+ levels and vasoconstriction in mesenteric resistance vessels. Endocrinology. In press.
31. Dubey RK, Gillespie DG, Jackson EK. Adenosine inhibits collagen and protein synthesis in cardiac fibroblasts: role of A2B receptors. Hypertension. 1998; 31: 943–948.
32. Daly RJ. Cortactin signalling and dynamic actin networks. Biochem J. 2004; 382: 13–25.[CrossRef][Medline] [Order article via Infotrieve]
33. Pu Q, Neves MF, Virdis A, Touyz RM, Schiffrin EL. Endothelin antagonism on aldosterone-induced oxidative stress and vascular remodeling. Hypertension. 2003; 42: 49–55.
34. Nishiyama A, Yao L, Nagai Y, Miyata K, Yoshizumi M, Kagami S, Kondo S, Kiyomoto H, Shokoji T, Kimura S, Kohno M, Abe Y. Possible contributions of reactive oxygen species and mitogen-activated protein kinase to renal injury in aldosterone/salt-induced hypertensive rats. Hypertension. 2004; 43: 841–848.
35. Haseroth K, Christ M, Falkenstein E, Wehling M. Aldosterone- and progesterone-membrane-binding proteins: new concepts of nongenomic steroid action. Curr Protein Pept Sci. 2000; 1: 385–401.[CrossRef][Medline] [Order article via Infotrieve]
36. Haseroth K, Gerdes D, Berger S, Feuring M, Gunther A, Herbst C, Christ M, Wehling M. Rapid nongenomic effects of aldosterone in mineralocorticoid-receptor-knockout mice. Biochem Biophys Res Commun. 1999; 266: 257–261.[CrossRef][Medline] [Order article via Infotrieve]
37. Rossol-Haseroth K, Zhou Q, Braun S, Boldyreff B, Falkenstein E, Wehling M, Losel RM. Mineralocorticoid receptor antagonists do not block rapid ERK activation by aldosterone. Biochem Biophys Res Commun. 2004; 318: 281–288.[CrossRef][Medline] [Order article via Infotrieve]
This article has been cited by other articles:
 |
|
 |
|
  M. M. Shafiq and A. B. Miller Blocking aldosterone in heart failure Therapeutic Advances in Cardiovascular Disease, October 1, 2009; 3(5): 379 - 385. [Abstract] [PDF]
|
|
|
|
 |
|
 A. Hirata, N. Maeda, A. Hiuge, T. Hibuse, K. Fujita, T. Okada, S. Kihara, T. Funahashi, and I. Shimomura Blockade of mineralocorticoid receptor reverses adipocyte dysfunction and insulin resistance in obese mice Cardiovasc Res, October 1, 2009; 84(1): 164 - 172. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Nakamura, K. Kataoka, M. Fukuda, H. Nako, Y. Tokutomi, Y.-F. Dong, H. Ichijo, H. Ogawa, and S. Kim-Mitsuyama Critical Role of Apoptosis Signal-Regulating Kinase 1 in Aldosterone/Salt-Induced Cardiac Inflammation and Fibrosis Hypertension, September 1, 2009; 54(3): 544 - 551. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. R. Sowers, A. Whaley-Connell, and M. Epstein Narrative Review: The Emerging Clinical Implications of the Role of Aldosterone in the Metabolic Syndrome and Resistant Hypertension Ann Intern Med, June 2, 2009; 150(11): 776 - 783. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Huang, A. Zhang, G. Ding, and R. Chen Aldosterone-induced mesangial cell proliferation is mediated by EGF receptor transactivation Am J Physiol Renal Physiol, June 1, 2009; 296(6): F1323 - F1333. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S.-G. Wei, Y. Yu, Z.-H. Zhang, and R. B. Felder Angiotensin II upregulates hypothalamic AT1 receptor expression in rats via the mitogen-activated protein kinase pathway Am J Physiol Heart Circ Physiol, May 1, 2009; 296(5): H1425 - H1433. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Wada, S. Ohshima, E. Fujisawa, D. Koya, H. Tsuneki, and T. Sasaoka Aldosterone Inhibits Insulin-Induced Glucose Uptake by Degradation of Insulin Receptor Substrate (IRS) 1 and IRS2 via a Reactive Oxygen Species-Mediated Pathway in 3T3-L1 Adipocytes Endocrinology, April 1, 2009; 150(4): 1662 - 1669. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Goto, F. Otsuka, M. Yamashita, J. Suzuki, H. Otani, H. Takahashi, T. Miyoshi, Y. Mimura, T. Ogura, and H. Makino Enhancement of aldosterone-induced catecholamine production by bone morphogenetic protein-4 through activating Rho and SAPK/JNK pathway in adrenomedullar cells Am J Physiol Endocrinol Metab, April 1, 2009; 296(4): E904 - E916. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Jeong, D. F. Chaupin, K. Matsushita, M. Yamakuchi, S. J. Cameron, C. N. Morrell, and C. J. Lowenstein Aldosterone activates endothelial exocytosis PNAS, March 10, 2009; 106(10): 3782 - 3787. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Yogi, G. E. Callera, R. Tostes, and R. M. Touyz Bradykinin regulates calpain and proinflammatory signaling through TRPM7-sensitive pathways in vascular smooth muscle cells Am J Physiol Regulatory Integrative Comp Physiol, February 1, 2009; 296(2): R201 - R207. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Leroy, S. De Seigneux, V. Agassiz, U. Hasler, M.-E. Rafestin-Oblin, M. Vinciguerra, P.-Y. Martin, and E. Feraille Aldosterone Activates NF-{kappa}B in the Collecting Duct J. Am. Soc. Nephrol., January 1, 2009; 20(1): 131 - 144. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Lopez-Andres, C. Inigo, I. Gallego, J. Diez, and M. A. Fortuno Aldosterone Induces Cardiotrophin-1 Expression in HL-1 Adult Cardiomyocytes Endocrinology, October 1, 2008; 149(10): 4970 - 4978. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A.C. Montezano, G.E. Callera, A. Yogi, Y. He, R.C. Tostes, G. He, E.L. Schiffrin, and R.M. Touyz Aldosterone and Angiotensin II Synergistically Stimulate Migration in Vascular Smooth Muscle Cells Through c-Src-Regulated Redox-Sensitive RhoA Pathways Arterioscler Thromb Vasc Biol, August 1, 2008; 28(8): 1511 - 1518. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Zanchi, C. Zoja, M. Morigi, F. Valsecchi, X. Y. Liu, D. Rottoli, M. Locatelli, S. Buelli, A. Pezzotta, P. Mapelli, et al. Fractalkine and CX3CR1 Mediate Leukocyte Capture by Endothelium in Response to Shiga Toxin J. Immunol., July 15, 2008; 181(2): 1460 - 1469. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Sontia, A. C.I. Montezano, T. Paravicini, F. Tabet, and R. M. Touyz Downregulation of Renal TRPM7 and Increased Inflammation and Fibrosis in Aldosterone-Infused Mice: Effects of Magnesium Hypertension, April 1, 2008; 51(4): 915 - 921. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Iwashima, T. Yoshimoto, I. Minami, M. Sakurada, Y. Hirono, and Y. Hirata Aldosterone Induces Superoxide Generation via Rac1 Activation in Endothelial Cells Endocrinology, March 1, 2008; 149(3): 1009 - 1014. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. L. Schiffrin New Twist to the Role of the Renin-Angiotensin System in Heart Failure: Aldosterone Upregulates Renin-Angiotensin System Components in the Brain Hypertension, March 1, 2008; 51(3): 622 - 623. [Full Text] [PDF]
|
|
|
|
|
|
Z.-H. Zhang, Y. Yu, Y.-M. Kang, S.-G. Wei, and R. B. Felder Aldosterone acts centrally to increase brain renin-angiotensin system activity and oxidative stress in normal rats Am J Physiol Heart Circ Physiol, February 1, 2008; 294(2): H1067 - H1074. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. J. Brown Aldosterone and Vascular Inflammation Hypertension, February 1, 2008; 51(2): 161 - 167. [Full Text] [PDF]
|
|
|
|
|
|
H. Hitomi, H. Kiyomoto, A. Nishiyama, T. Hara, K. Moriwaki, K. Kaifu, G. Ihara, Y. Fujita, T. Ugawa, and M. Kohno Aldosterone Suppresses Insulin Signaling Via the Downregulation of Insulin Receptor Substrate-1 in Vascular Smooth Muscle Cells Hypertension, October 1, 2007; 50(4): 750 - 755. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Yogi, G.E. Callera, A.C.I. Montezano, A.B. Aranha, R.C. Tostes, E.L. Schiffrin, and R.M. Touyz Endothelin-1, but not Ang II, Activates MAP Kinases Through c-Src-Independent Ras-Raf-Dependent Pathways in Vascular Smooth Muscle Cells Arterioscler Thromb Vasc Biol, September 1, 2007; 27(9): 1960 - 1967. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Nietlispach, B. Julius, R. Schindler, A. Bernheim, C. Binkert, W. Kiowski, and H. P. Brunner-La Rocca Influence of Acute and Chronic Mineralocorticoid Excess on Endothelial Function in Healthy Men Hypertension, July 1, 2007; 50(1): 82 - 88. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Otani, F. Otsuka, K. Inagaki, M. Takeda, T. Miyoshi, J. Suzuki, T. Mukai, T. Ogura, and H. Makino Antagonistic effects of bone morphogenetic protein-4 and -7 on renal mesangial cell proliferation induced by aldosterone through MAPK activation Am J Physiol Renal Physiol, May 1, 2007; 292(5): F1513 - F1525. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Hirono, T. Yoshimoto, N. Suzuki, T. Sugiyama, M. Sakurada, S. Takai, N. Kobayashi, M. Shichiri, and Y. Hirata Angiotensin II Receptor Type 1-Mediated Vascular Oxidative Stress and Proinflammatory Gene Expression in Aldosterone-Induced Hypertension: The Possible Role of Local Renin-Angiotensin System Endocrinology, April 1, 2007; 148(4): 1688 - 1696. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. Jung, S. L. Marklund, N. Xia, R. Busse, and R. P. Brandes Inactivation of Extracellular Superoxide Dismutase Contributes to the Development of High-Volume Hypertension Arterioscler Thromb Vasc Biol, March 1, 2007; 27(3): 470 - 477. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.-K. Park, R. Fischer, R. Dechend, E. Shagdarsuren, A. Gapeljuk, M. Wellner, S. Meiners, P. Gratze, N. Al-Saadi, S. Feldt, et al. p38 Mitogen-Activated Protein Kinase Inhibition Ameliorates Angiotensin II-Induced Target Organ Damage Hypertension, March 1, 2007; 49(3): 481 - 489. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Yu, Y.-M. Kang, Z.-H. Zhang, S.-G. Wei, Y. Chu, R. M. Weiss, and R. B. Felder Increased Cyclooxygenase-2 Expression in Hypothalamic Paraventricular Nucleus in Rats With Heart Failure: Role of Nuclear Factor {kappa}B Hypertension, March 1, 2007; 49(3): 511 - 518. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Gros, Q. Ding, S. Armstrong, C. O'Neil, J. G. Pickering, and R. D. Feldman Rapid effects of aldosterone on clonal human vascular smooth muscle cells Am J Physiol Cell Physiol, February 1, 2007; 292(2): C788 - C794. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Shibata, M. Nagase, S. Yoshida, H. Kawachi, and T. Fujita Podocyte as the Target for Aldosterone: Roles of Oxidative Stress and Sgk1 Hypertension, February 1, 2007; 49(2): 355 - 364. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Bedard and K.-H. Krause The NOX Family of ROS-Generating NADPH Oxidases: Physiology and Pathophysiology Physiol Rev, January 1, 2007; 87(1): 245 - 313. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. M. Thobe, M. Frink, M. A. Choudhry, M. G. Schwacha, K. I. Bland, and I. H. Chaudry Src family kinases regulate p38 MAPK-mediated IL-6 production in Kupffer cells following hypoxia Am J Physiol Cell Physiol, September 1, 2006; 291(3): C476 - C482. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Marumo, H. Uchimura, M. Hayashi, K. Hishikawa, and T. Fujita Aldosterone Impairs Bone Marrow-Derived Progenitor Cell Formation Hypertension, September 1, 2006; 48(3): 490 - 496. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Johar, A. C. Cave, A. Narayanapanicker, D. J. Grieve, and A. M. Shah Aldosterone mediates angiotensin II-induced interstitial cardiac fibrosis via a Nox2-containing NADPH oxidase FASEB J, July 1, 2006; 20(9): 1546 - 1548. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Kobayashi, K. Yoshida, S. Nakano, T. Ohno, T. Honda, Y. Tsubokou, and H. Matsuoka Cardioprotective Mechanisms of Eplerenone on Cardiac Performance and Remodeling in Failing Rat Hearts Hypertension, April 1, 2006; 47(4): 671 - 679. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. L. Schiffrin Effects of Aldosterone on the Vasculature Hypertension, March 1, 2006; 47(3): 312 - 318. [Full Text] [PDF]
|
|
|
|
|
|
K. Miyata, M. Rahman, T. Shokoji, Y. Nagai, G.-X. Zhang, G.-P. Sun, S. Kimura, T. Yukimura, H. Kiyomoto, M. Kohno, et al. Aldosterone Stimulates Reactive Oxygen Species Production through Activation of NADPH Oxidase in Rat Mesangial Cells J. Am. Soc. Nephrol., October 1, 2005; 16(10): 2906 - 2912. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Nagai, K. Miyata, G.-P. Sun, M. Rahman, S. Kimura, A. Miyatake, H. Kiyomoto, M. Kohno, Y. Abe, M. Yoshizumi, et al. Aldosterone Stimulates Collagen Gene Expression and Synthesis Via Activation of ERK1/2 in Rat Renal Fibroblasts Hypertension, October 1, 2005; 46(4): 1039 - 1045. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Ishizawa, Y. Izawa, H. Ito, C. Miki, K. Miyata, Y. Fujita, Y. Kanematsu, K. Tsuchiya, T. Tamaki, A. Nishiyama, et al. Aldosterone Stimulates Vascular Smooth Muscle Cell Proliferation Via Big Mitogen-Activated Protein Kinase 1 Activation Hypertension, October 1, 2005; 46(4): 1046 - 1052. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. E. Callera, A. C. I. Montezano, A. Yogi, R. C. Tostes, Y. He, E. L. Schiffrin, and R. M. Touyz c-Src-Dependent Nongenomic Signaling Responses to Aldosterone Are Increased in Vascular Myocytes From Spontaneously Hypertensive Rats Hypertension, October 1, 2005; 46(4): 1032 - 1038. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Wehling Rapid Effects of Aldosterone: Relevant in Cardiac Ischemia? Hypertension, July 1, 2005; 46(1): 27 - 28. [Full Text] [PDF]
|
|
|
|
 |
|
 B. C. Blaxall, J. M. Miano, and B. C. Berk Angiotensin II: A Devious Activator of Mineralocorticoid Receptor-Dependent Gene Expression Circ. Res., April 1, 2005; 96(6): 610 - 611. [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||